CHU Helora
- Address
- lock Available on a paid plan
Nutritional and Metabolic Diseases
The Department of Endocrinology at CHU Helora is conducting research focused on Severe Hypertriglyceridemia, aiming to evaluate new therapeutic approaches that lower triglyceride levels and improve metabolic health.
- Evaluation of novel agents that reduce fasting serum triglycerides
- Assessment of safety and tolerability in metabolic disorder patients
- Long‑term impact on cardiovascular risk markers
These studies seek to provide better treatment options for patients with high triglyceride levels, addressing a key metabolic challenge.
Respiratory Tract Diseases
Research at CHU Helora also explores the interplay between metabolic dysfunction and respiratory physiology, investigating how systemic metabolic disorders affect lung health.
- Study of metabolic biomarkers in patients with respiratory conditions
- Impact of lipid‑lowering therapies on pulmonary function
- Integration of endocrine and respiratory care pathways
The goal is to improve diagnostic and therapeutic strategies for patients where metabolic and respiratory issues intersect.
Circulatory and Respiratory Physiological Phenomena
The site’s interdisciplinary trials examine circulatory and respiratory physiological processes in the context of both metabolic disease and hematologic malignancy such as relapsed or refractory diffuse large B‑cell lymphoma.
- Comparison of overall survival outcomes across treatment regimens
- Evaluation of cardiovascular effects of oncology therapies
- Analysis of physiological responses to combined metabolic and cancer treatments
By linking endocrine, cardiovascular, and oncologic research, the program aims to enhance patient management across multiple disease domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 185 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 178 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Janssen Cilag International6active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International11trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Helora
lock Showing 1 of 106 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 185 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 13 | Unknown | 2020-04-06 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.